Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 26, Issue 24, 2008, Pages 3979-3986

  Manegold, Christian ^a   Gravenor, Donald ^a   Woytowitz, Donald ^a   Mezger, Jörg ^a   Hirsh, Vera ^a   Albert, Gary ^a   Al Adhami, Mohammed ^a   Readett, David ^a   Krieg, Arthur M ^a   Leichman, Cynthia Gail ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CPG 7909; DOCETAXEL; PACLITAXEL; ANTINEOPLASTIC AGENT; OLIGODEOXYRIBONUCLEOTIDE; TAXOID; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOPTYSIS; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEAKNESS; CANCER STAGING; COMPARATIVE STUDY; DRUG POTENTIATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGODEOXYRIBONUCLEOTIDES; PACLITAXEL; TAXOIDS; TOLL-LIKE RECEPTOR 9;

EID: 50549084485     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.5807     Document Type: Article

References (41)

1. Felip E, Stahel RA, Pavlidis N: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 16:i28-i29, 2005 (suppl 1)
2. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
4. Smit EF, van Meerbeeck JP, Lianes P, et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 21:3909-3917, 2003
5. Souquet PJ, Tan EH, Rodrigues Pereira J, et al: GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 13:1853-1861, 2002
6. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
7. Alberola V, Camps C, Provencio M, et al: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21:3207-3213, 2003
8. Paccagnella A, Oniga F, Bearz A, et al: Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: Results of a phase II-III study. J Clin Oncol 24:681-687, 2006
9. Delbaldo C, Michiels S, Syz N, et al: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 292:470-484, 2004
10. Bissett D, O'Byrne KJ, von Pawel J, et al: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23:842-849, 2005
11. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al: Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 41:227-231, 2003
12. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004
13. Goffin JR, Anderson IC, Supko JG, et al: Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11:3417-3424, 2005
14. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004
15. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
16. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 23:2s, 2005 (suppl, abstr LBA4)
17. Manegold C, von Pawel J, Zatloukal P, et al: Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous nonsmall cell lung cancer (NSCLC): BO17704. J Clin Oncol 25:388s, 2007 (suppl, abstr LBA7514)
18. Krieg AM: Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6:88-95, 2004
19. Krieg AM: Development of TLR9 agonists for cancer therapy. J Clin Invest 117:1184-1194, 2007
20. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5:471-484, 2006
21. Manegold C, Leichman G, Gravenor D, et al: Addition of CPG 7909 to taxane/platinum regimen for first-line treatment of unresectable NSCLC improves objective response in phase II clinical trial. Presented at ECCO 13 - the European Cancer Conference, Paris, France, October 30-November 3, 2005 (abstr 1131)
22. Pashenkov M, Goess G, Wagner C, et al: Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24:5716-5724, 2006
23. Thompson JA, Kuzel T, Bukowski R, et al: Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). J Clin Oncol 22:16s, 2004 (suppl, abstr 4644)
24. Kim Y, Girardi M, McAuley S, et al: Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CpG immunomodulator (CPG 7909), a phase I study. J Clin Oncol 22:580s, 2004 (suppl, abstr 6600)
25. Weeratna RD, Bourne LL, Sullivan SM, et al: Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma (LLC). J Clin Oncol 22:699, 2004 (suppl, abstr 7346)
26. Balsari A, Tortoreto M, Besusso D, et al: Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 40:1275-1281, 2004
27. Wang XS, Sheng Z, Ruan YB, et al: CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol 11:1220-1224, 2005
28. Weigel BJ, Rodeberg DA, Krieg AM, et al: CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 9:3105-3114, 2003
29. Pratesi G, Petrangolini G, Tortoreto M, et al: Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 65:6388-6393, 2005
30. Wang H, Rayburn ER, Wang W, et al: Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 5:1585-1592, 2006
31. van der Most RG, Himbeck R, Aarons S, et al: Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides. J Immunother 29:134-142, 2006
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Cox DR: Regression models and life-tables. J R Stat Soc [B] 34:187-220, 1972
34. Edelman MJ, Clark JI, Chansky K, et al: Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022-5026, 2004
35. Wakelee H, Belani CP: Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10:1-10, 2005 (suppl 3)
36. Krieg AM: Anti-infective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 4:289-294, 2007
37. Traggiai E, Becker S, Subbarao K, et al: An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 10:871-875, 2004
38. Droemann D, Albrecht D, Gerdes J, et al: Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6:1, 2005
39. Carson WE 3rd, Shapiro CL, Crespin TR, et al: Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 10:3401-3409, 2004
40. Lake RA, Robinson BW: Immunotherapy and chemotherapy: A practical partnership. Nat Rev Cancer 5:397-405, 2005
41. Lutsiak ME, Semnani RT, De Pascalis R, et al: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868, 2005